The Food and Drug Administration has moved to resolve a regulatory tangle around N-acetyl-L-cysteine (NAC). The agency issued a proposed rule that would create a new designation — a “Dietary Ingredient Not Excluded from the Dietary Supplement Definition” — specifically for NAC, the STAT article reported. The proposal appears to be the first time the FDA has deployed that label for a constituent widely sold over the counter.
The report said the change directly addresses a legal inconsistency that previously left NAC in a gray area. NAC has been available in retail stores for years as an over-the-counter supplement. Yet the compound also has historical approvals as a drug, and federal regulations ordinarily bar products that were previously approved as drugs from qualifying as dietary supplements.
The article traced the regulatory problem to two earlier FDA drug approvals for NAC. The agency first approved the compound to break up mucus in certain lung conditions in 1963. Later, in 1985, NAC received approval for treatment of acetaminophen overdose. Those approvals, the piece noted, are the reasons NAC has faced exclusion under the dietary supplement definition.
Consumers and sellers nonetheless continued to market and buy NAC-containing products. The STAT reporting attributed the persistence of OTC NAC products to a long-running legal ambiguity — despite the drug approvals, NAC continued to circulate in the supplement aisle. Members of supplement advocacy circles, including proponents aligned with the MAHA movement, supported the proposed regulatory fix, the story said.
The proposed rule would formally classify NAC as not excluded from the definition of a dietary supplement, according to STAT. That change, if finalized, would permit NAC to be sold and regulated under the framework that governs dietary supplements rather than being categorically barred because of prior drug approvals. The article described this as a direct response by the agency to the practical reality of NAC’s widespread retail availability.
STAT linked to the FDA posting announcing the proposed rule. The article did not reproduce the full text of the FDA rationale, nor did it report details such as proposed labeling requirements, enforcement timelines, or conditions that might accompany the new designation. The piece focused on the regulatory shift and its political and policy context rather than operationalizing how manufacturers would comply.
Several concrete questions remain unanswered in the STAT account. The article did not provide the final regulatory language from the FDA beyond describing the proposed classification. It also did not report any implementation timetable, compliance expectations for manufacturers, or how existing NAC products would be transitioned into the supplement regulatory scheme. The story did not include statements from the FDA beyond linking to the proposal, nor did it quote industry groups, clinicians, or patient advocates other than noting MAHA-aligned supporters welcomed the move.
Clinical and safety specifics were likewise absent. The article did not supply dosing guidance, benefit-risk reviews, or new safety data for NAC products. Readers seeking the agency’s detailed rationale or the regulatory text will need to consult the FDA posting the article referenced; the STAT piece itself is behind a STAT+ subscriber wall and directed readers to the FDA link for the official notice.
The STAT report placed the announcement in a policy context rather than a clinical one. It highlighted the historical approvals from 1963 and 1985 as the legal basis for the prior exclusion, and it framed the proposal as resolving a regulatory inconsistency that allowed OTC NAC commerce to continue. The article stopped short of offering a timeline for final rulemaking or describing any subsequent administrative steps the FDA might take.
Limitations and next steps documented in the source
The article made clear that the posted proposed rule is just that — proposed. STAT did not report a final agency decision, nor did it report procedural milestones such as a public-comment deadline or projected effective date. The piece also noted that additional, operational details were available only in the linked FDA announcement and that the STAT story itself withheld the full text for subscribers. Those gaps remain the outstanding, documented questions following the announcement.